Impact of genetic polymorphisms on clinical response to antithrombotics

References

• Lloyd-JonesDAdamsRCarnethonMHeart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation20091193e21e18119075105
   PubMed Web of Science ®Google Scholar
• AndersonJLAdamsCDAntmanEMACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency MedicineCirculation20071167e148e30417679616
   PubMed Web of Science ®Google Scholar
• SaccoRLAdamsRAlbersGGuidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guidelineCirculation200611310e409e4916534023
   PubMed Web of Science ®Google Scholar
• HirschATHaskalZJHertzerNRACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease FoundationCirculation200611311e463e65416549646
   PubMed Web of Science ®Google Scholar
• FusterVRydenLECannomDSACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm SocietyCirculation20061147e257e35416908781
   PubMed Web of Science ®Google Scholar
• HirshJGuyattGAlbersGWHarringtonRSchunemannHJExecutive summary: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)Chest20081336 Suppl71S109S18574259
   PubMed Web of Science ®Google Scholar
• SteinhublSRBergerPBMannJT3rdEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trialJAMA2002288192411242012435254
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSRChrolaviciusSTognoniGFoxKKEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med2001345749450211519503
   PubMed Web of Science ®Google Scholar
• BonelloLCamoin-JauLArquesSAdjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective studyJ Am Coll Cardiol200851141404141118387444
   PubMed Web of Science ®Google Scholar
• GorogDASweenyJMFusterVAntiplatelet drug ‘resistance’. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?Nat Rev Cardiol20096536537319365406
   PubMed Web of Science ®Google Scholar
• O’DonoghueMLBraunwaldEAntmanEMPharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trialsLancet2009374969498999719726078
   PubMed Web of Science ®Google Scholar
• SawJSteinhublSRBergerPBLack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trialCirculation2003108892192412925453
   PubMed Web of Science ®Google Scholar
• KroeseMZimmernRLPinderSEHER2 status in breast cancer--an example of pharmacogenetic testingJ R Soc Med2007100732632917606754
   PubMed Web of Science ®Google Scholar
• HuangEIshidaSPittmanJGene expression phenotypic models that predict the activity of oncogenic pathwaysNat Genet200334222623012754511
   PubMed Web of Science ®Google Scholar
• MoyerTPO’KaneDJBaudhuinLMWarfarin sensitivity genotyping: a review of the literature and summary of patient experienceMayo Clin Proc200984121079109419955245
   PubMed Web of Science ®Google Scholar
• StehleSKirchheinerJLazarAFuhrUPharmacogenetics of oral anticoagulants: a basis for dose individualizationClin Pharmacokinet200847956559418698879
   PubMed Web of Science ®Google Scholar
• RettieAEWienkersLCGonzalezFJTragerWFKorzekwaKRImpaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics19944139428004131
   PubMedGoogle Scholar
• HigashiMKVeenstraDLKondoLMAssociation between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapyJAMA2002287131690169811926893
   PubMed Web of Science ®Google Scholar
• WadeliusMChenLYLindhJDThe largest prospective warfarin-treated cohort supports genetic forecastingBlood2009113478479218574025
   PubMed Web of Science ®Google Scholar
• LindhJDLundgrenSHolmLAlfredssonLRaneAseveral-fold increase in risk of overanticoagulation by CYP2C9 mutationsClin Pharmacol Ther200578554055016321620
   PubMed Web of Science ®Google Scholar
• HermanDLocatelliIGrabnarIInfluence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dosePharmacogenomics J20055319320215824753
   PubMed Web of Science ®Google Scholar
• AndersonJLHorneBDStevensSMRandomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulationCirculation2007116222563257017989110
   PubMed Web of Science ®Google Scholar
• KleinTEAltmanRBErikssonNEstimation of the warfarin dose with clinical and pharmacogenetic dataN Engl J Med2009360875376419228618
   PubMed Web of Science ®Google Scholar
• Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative GroupLancet1988286073493602899772
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists’ CollaborationCollaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ20023247329718611786451
   PubMed Web of Science ®Google Scholar
• FeherGFeherAPuschGLupkovicsGSzaparyLPappEThe genetics of antiplatelet drug resistanceClin Genet200975111819067731
   PubMed Web of Science ®Google Scholar
• CuissetTFrereCQuiliciJAspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stentingAm Heart J2009157588989319376317
   PubMed Web of Science ®Google Scholar
• MacchiLChristiaensLBrabantSResistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphismsJ Am Coll Cardiol20034261115111913678940
   PubMed Web of Science ®Google Scholar
• MareeAOCurtinRJChubbACyclooxygenase-1 haplotype modulates platelet response to aspirinJ Thromb Haemost20053102340234516150050
   PubMed Web of Science ®Google Scholar
• LepantaloAMikkelssonJResendizJCPolymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patientsThromb Haemost200695225325916493486
   PubMed Web of Science ®Google Scholar
• LevEIPatelRTGuthikondaSLopezDBrayPFKleimanNSGenetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrelThromb Res2007119335536016581111
   PubMed Web of Science ®Google Scholar
• BrandtJTCloseSLIturriaSJCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost20075122429243617900275
   PubMed Web of Science ®Google Scholar
• LauWCGurbelPAWatkinsPBContribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistanceCirculation2004109216617114707025
   PubMed Web of Science ®Google Scholar
• BrackbillMLKiddRSAbdooADWarnerJGJrHarralsonAFFrequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndromeHeart Vessels2009242737819337788
   PubMed Web of Science ®Google Scholar
• SuhJWKooBKZhangSYIncreased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrelCMAJ2006174121715172216754899
   PubMed Web of Science ®Google Scholar
• SimonTVerstuyftCMary-KrauseMGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med2009360436337519106083
   PubMed Web of Science ®Google Scholar
• TrenkDHochholzerWFrommMFCytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stentsJ Am Coll Cardiol200851201925193418482659
   PubMed Web of Science ®Google Scholar
• ShuldinerARO’ConnellJRBlidenKPAssociation of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyJAMA2009302884985719706858
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome p-450 polymorphisms and response to clopidogrelN Engl J Med2009360435436219106084
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomesCirculation2009119192553256019414633
   PubMed Web of Science ®Google Scholar
• BhattDLCHARISMA Genomics Substudy links loss-of-function allele and bleedingPresented at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting2009 [cited 2009 Dec 11]. URL: http://www.theheart.org/article/1008623.do
   Google Scholar
• Scripps HealthIndividualized therapies now available for anti-clogging medications [press release]1072009 URL:http://www.scripps.org/news_items/3521-scripps-becomes-first-in-u-s-to-offer-genetic-tests-to-stent-patients
   Google Scholar
• WallentinLBeckerRCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med2009361111045105719717846
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar